Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Internet-based Group Contingency Management to Promote Smoking Abstinence

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jesse Dallery, National Development and Research Institutes, Inc.
ClinicalTrials.gov Identifier:
NCT01181661
First received: August 12, 2010
Last updated: September 23, 2014
Last verified: September 2014

August 12, 2010
September 23, 2014
August 2010
August 2013   (final data collection date for primary outcome measure)
Breath CO [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Twice daily breath CO samples obtained during baseline and treatment
Same as current
Complete list of historical versions of study NCT01181661 on ClinicalTrials.gov Archive Site
  • Point prevalence measure of abstinence [ Time Frame: at the end of treatment (approximately week 4) and at 3 month follow-up ] [ Designated as safety issue: No ]
    Abstinence will be defined as: (a) CO sample ≤ 4 ppm; (b) cotinine < 50 ng/ml; and (c) reporting not smoking, not even a puff in the last 7 days.
  • Duration of abstinence during treatment. [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    The longest duration of sustained abstinence (CO ≤ 4 ppm) based on the twice-daily breath samples during the treatment period.
  • Rate of social exchanges [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    The number of comments posted on the discussion forum during treatment.
Same as current
Not Provided
Not Provided
 
Internet-based Group Contingency Management to Promote Smoking Abstinence
Internet-based Group Contingency Management to Promote Smoking Abstinence

The purpose of the study is to develop and test an Internet-based group contingency management program designed to promote smoking cessation.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Treatment
Cigarette Smoking
  • Behavioral: Full Group Contingency
    This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
  • Behavioral: Mixed Group Contingency
    This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
  • Experimental: Full Group Contingency
    This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
    Intervention: Behavioral: Full Group Contingency
  • Experimental: Mixed Group Contingency
    This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
    Intervention: Behavioral: Mixed Group Contingency
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
August 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • self-reported smoker
  • ability to use the Internet
  • permission to contact applicant by phone

Exclusion Criteria:

  • self-report of a history of or current severe or unstable medical or psychiatric illness that would interfere with the study
  • inability to avoid high levels of ambient CO (e.g., occupational exposure; lives with a another smoker who smokes in the home)
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01181661
1R21DA029162, 1R21DA029162
No
Jesse Dallery, National Development and Research Institutes, Inc.
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)
Principal Investigator: Jesse Dallery, PhD National Development and Research Institutes, Inc.
National Development and Research Institutes, Inc.
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP